A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Imago BioSciences
Start Date
October 2, 2020
End Date
December 28, 2023
Administered By
Duke Cancer Institute
Awarded By
Imago BioSciences
Start Date
October 2, 2020
End Date
December 28, 2023